BMN 044Alternative Names: BMN044; Exon 44 specific phosphorothioate oligonucleotide; H44aon188; PRO044; PS 188
Latest Information Update: 26 Jul 2016
At a glance
- Originator Prosensa
- Developer BioMarin Nederland
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA modulators; Dystrophin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Duchenne muscular dystrophy